Lyell Immunopharma Inc (LYEL)
1.28
+0.16
(+14.29%)
USD |
NASDAQ |
Nov 04, 16:00
1.31
+0.03
(+2.34%)
After-Hours: 07:32
Lyell Immunopharma Enterprise Value: -163.44M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -163.44M |
| November 01, 2024 | -204.40M |
| October 31, 2024 | -245.28M |
| October 30, 2024 | -271.39M |
| October 29, 2024 | -248.40M |
| October 28, 2024 | -251.50M |
| October 25, 2024 | -253.80M |
| October 24, 2024 | -212.08M |
| October 23, 2024 | -196.72M |
| October 22, 2024 | -196.72M |
| October 21, 2024 | -204.40M |
| October 18, 2024 | -191.60M |
| October 17, 2024 | -189.04M |
| October 16, 2024 | -171.12M |
| October 15, 2024 | -191.60M |
| October 14, 2024 | -186.48M |
| October 11, 2024 | -189.04M |
| October 10, 2024 | -212.08M |
| October 09, 2024 | -214.64M |
| October 08, 2024 | -201.84M |
| October 07, 2024 | -201.84M |
| October 04, 2024 | -178.80M |
| October 03, 2024 | -186.48M |
| October 02, 2024 | -176.24M |
| October 01, 2024 | -163.44M |
| Date | Value |
|---|---|
| September 30, 2024 | -137.83M |
| September 27, 2024 | -104.55M |
| September 26, 2024 | -101.99M |
| September 25, 2024 | -145.51M |
| September 24, 2024 | -117.35M |
| September 23, 2024 | -125.03M |
| September 20, 2024 | -104.55M |
| September 19, 2024 | -91.75M |
| September 18, 2024 | -145.51M |
| September 17, 2024 | -135.27M |
| September 16, 2024 | -173.68M |
| September 13, 2024 | -176.24M |
| September 12, 2024 | -196.72M |
| September 11, 2024 | -196.72M |
| September 10, 2024 | -196.72M |
| September 09, 2024 | -201.84M |
| September 06, 2024 | -191.60M |
| September 05, 2024 | -163.44M |
| September 04, 2024 | -137.83M |
| September 03, 2024 | -132.71M |
| August 30, 2024 | -119.91M |
| August 29, 2024 | -117.35M |
| August 28, 2024 | -119.91M |
| August 27, 2024 | -117.35M |
| August 26, 2024 | -84.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-271.39M
Minimum
Oct 30 2024
4.507B
Maximum
Jun 17 2021
627.54M
Average
175.41M
Median
Feb 28 2024
Enterprise Value Benchmarks
| Ocular Therapeutix Inc | 1.209B |
| Marinus Pharmaceuticals Inc | 10.41M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 9.837M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.81M |
| Revenue (Quarterly) | 0.013M |
| Total Expenses (Quarterly) | 51.54M |
| EPS Diluted (Quarterly) | -0.18 |
| Profit Margin (Quarterly) | -352.4K% |
| Earnings Yield | -64.06% |
| Normalized Earnings Yield | -60.07 |